2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Thalassemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

4251 Targeting sphingosine 1-phosphate receptor 1/5 (S1PR1/5) reduces T-cell pathogenicity in graft-versus-host disease

Xue-Zhong Yu Sr, MD, MSc, Xiaohong Yuan Sr, MD2
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Fujian Medical University Union Hospital, Fuzhou, Fujian, China, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Steroid-refractory Graft-versus-host disease (SR-GVHD) is remain a vexing challenge for patient high mortality after allogeneic hematopoietic cell transplantation (allo-HCT). Previous studies demonstrated that antagonizing sphingosine-1-phosphate recepter1 (S1PR1) on T cells reduced T-cell infiltration into GVHD target tissues and alleviated GVHD after murine models of allo-HCT, and attempt to translate it into clinical practice. However, given overlapping functions of S1PRs, it is unclear whether independent or coordinated antagonism of multiple S1PRs (s1pr1, s1pr4 and s1pr5) will achieve a better efficiency in alleviating GVHD. Here, T-cell conditional S1PR1−/− mice (S1pr1flox/floxCD4Cre, H2Kb, Ly5.2+), germline S1pr4−/− and S1pr5−/− on a C57BL/6 background were used. MHC-mismatched and haploidentical bone marrow transplantation (BMT) models were established using BABL/c and B6D2F1 mice as recipients, respectively.  Xenograft model was established with NSG HLA-A2+ mice, which were irradiated and transfused with HLA-A2− human PBMCs. Ozanimod (2mg/kg daily) or Siponimod (2mg/kg daily) gavage to the recipients from day 0 to 14 after BMT. Representative samples of GVHD target organs were collected from recipients on day 14 or 21 after BMT and subjected to pathology scoring or flow cytometry. Single cell RNA sequencing (scRNAseq) was performed in T cells isolated from intestinal tissues of GVHD recipients. Using gene knock-out (KO) mice as donors, we confirmed that S1pr1-KO T cells significantly alleviated GVHD. We found that S1pr5-KO T cells exacerbate murine GVHD after allo-HCT while S1pr4-KO T cells induced comparable GVHD as WT T cells.  Deficiency of S1pr1 in T cells significantly reduced donor T-cell infiltration into GVHD target organs. In contrast, S1pr5 deficiency increased the number of CD8+ donor T cells in the GVHD target organs, especially of tissue-resident memory (TRM, CD69+CD103+) T cells in gut and liver. S1pr5 deficiency in T cells also increased inflammatory cytokine secretion in recipient spleen and GVHD target organs. The scRNAseq analysis of colon intraepithelial lymphocytes showed that S1pr5 KO T cells predominately expanded CD8+ over CD4 T cells, with accumulation of tissue-resident memory and effector-like CD8+ cells. Furthermore, deficiency of both S1pr1 and S1pr5 in T cells significantly alleviated acute GVHD similarly to S1pr1 single deficiency. In parallel, treatment of recipients with either ozanimod (S1PR1 antagonist in mice) or siponimod (S1PR1/5 antagonist) significantly reduced GVHD severity.  However, the recipients treated with siponimod exhibited more severe chronic GVHD than those with ozanimod. Furthermore, the treatment of recipients with a S1PR1&5 antagonist significantly alleviate GVHD induced by human T cells in xenograft GVHD model. Mechanistically, inhibition of S1PR1&5 reduced the number of IFNg+ T-cell infiltration in recipient spleen and liver, while retained more T cells with naïve phenotype. In conclusion, S1PR1 plays a dominant role in regulating T-cell pathogenicity in GVHD, but the sole antagonism of S1PR5 could exacerbate GVHD. Given several S1PR antagonists have been approved by FDA for treating autoimmune diseases, especially in inflammatory bowel disease, our findings provide rationale to evaluate these modulators in the prevention of gut GVHD in clinic.
Xiaohong Yuan Sr, MD: No relevant conflicts of interest to declare.